Factors associated with severe postpartum haemorrhage: systematic review using Bradford Hill’s causality framework

Tatiana Stachetti*, Michel Spodenkiewicz‡, Arnaud Winer†, Malik Boukerrou**, Julie Jesson††, Patrick Gérardin‡‡

Keywords: maternal mortality, post partum hemorrhage, global health

https://doi.org/10.29392/joghr.3.e2019085

Background
Severe postpartum haemorrhage (S-PPH) is the leading cause of maternal death worldwide. We aimed to provide an up-to-date summary about S-PPH determinants.

Methods
We performed a systematic review following the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines. We searched the terms "risk factor", "determinant", "post-partum haemorrhage" and "severe", within Web of Science, Scopus, Science Direct, Medline, Cochrane, and Clinical Trials.gov databases. The primary endpoint was S-PPH, defined as a blood loss ≥ 1,000 mL a second-line treatment, a PPH-related blood transfusion, a peripartum decrease in haemoglobin level or a PPH-related maternal death. All interventional and observational studies about risks factors for S-PPH published in English or French between January 1, 2004 and August 31, 2018 were eligible. Because studies used very different definitions of S-PPH, meta-analysis was ruled out and we gauged the risk factors using the Bradford Hill’s criteria causality framework.

Results
Amongst 1,193 identified abstracts, we selected fourteen studies that collected information on 9,271,519 parturient women (35,825 with S-PPH). Key established determinants of S-PPH were previous PPH, previous caesarean, multiple pregnancy, abnormal placentation, preeclampsia, labour induction, prolonged labour, placental retention, uterine rupture, uterine atony, uterine fibroids, macrosomia, birth canal injuries, instrumental vaginal and caesarean deliveries. Most of associated factors of uncertain significance belonged to socio-environmental characteristics. Biological parameters were all classified as indicators of risk.

Conclusions
The key established determinants of S-PPH are of primarily obstetrical nature. New avenues of research, including contextual studies, are needed to improve the management of severe obstetrical morbidity.

Despite global effort to reduce maternal mortality, post-partum haemorrhage (PPH) is the leading cause of maternal death worldwide. PPH accounts for a large majority of obstetrical haemorrhages and severe obstetrical morbidity. 1

PPH is usually defined as blood loss of at least 500 mL, 700 mL, or 1,000 mL, according to its different guidelines. 1–2 At population level, the incidence of PPH is estimated about 5% of total live births—this number varying greatly between regions and obstetric centres. Severe PPH (S-PPH), currently defined as blood loss of more than 1,000 mL accounts for about 1% of total deliveries (~20% of all parturient women). 1–2

Several individual risk factors for PPH and S-PPH have been reported in the literature, including non-obstetrical and obstetrical determinants. 3, 4 Thus, greater attention has been paid during the last decade to the medical management of S-PPH, as it may lead to further improvements with an important impact on the disease burden.

In accordance, studies have been conducted to establish recommendations for clinical practice in managing childbirth. Nevertheless, most of these studies have focused on the period of labour and did not fully account, either for non-obstetrical individual or antepartum obstetrical individual risk factors. 3, 6 Furthermore, the quality of care in
Factors associated with severe postpartum haemorrhage: systematic review using Bradford Hill’s causality framework

obstetrics is a major global health concern that requires continuous improvements. In this sense, conducting regular updates of the literature on the determinants of S-PPH can help to account for the evolution of knowledge and practices, quality emergency obstetric care (EmOC) while in turn it may also contribute to mitigating maternal risks through improving the triage and treatment of parturient women.

In this framework, we provided an up-to-date summary about the determinants for S-PPH. Our first hypothesis was that certain maternal conditions (age at first parity, grand multiparity, obesity, stress, depression, etc.) which are increasing in western countries and are classically associated with some PPH determinants (pre-eclampsia, caesarean section, instrumental extractions) could contribute to an increase in the incidence of PPH. Our second hypothesis was that the lack of identification, upstream of organizational measures aimed at preventing PPH, pushed to focus efforts on individual obstetrical care, which could be hampered by the deterioration of socio-economic conditions and access to prevention, thus facilitating the risk of S-PPH at presentation. We deduced from the above the possibility that determinants of PPH upstream of childbirth could emerge, with a strong probability that those which are not very dependent on obstetrical care, could be also associated with progression from PPH to S-PPH. Our primary objective was to identify and classify the determinants of S-PPH for decision-making purposes.

METHODS
SEARCH STRATEGY AND STUDY SELECTION

This systematic review was developed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Appendix S1 in the Online Supplementary Document). 7

Using the terms "risk factor", OR "determinant", AND "post-partum haemorrhage" AND "severe", we searched Web of Science, Scopus, Science Direct, Medline, Cochrane (Pregnancy and Childbirth Group’s Register), ClinicalTrials.gov databases, for both interventional and observational studies (randomized controlled trials; either cross-sectional, case-control or cohort studies, respectively) published in English language, between January 1, 2004 and August 31, 2018. The full search strategy is detailed in the protocol provided in Appendix S2 of the Online Supplementary Document.

Abstracts of identified articles were screened independently by two reviewers (TS, PG) to verify whether they matched the selection criteria. Inter-observer discrepancies were resolved by arbitration of a third reviewer (MS). Searches were complemented by consulting with experts in the field.

Study eligibility criteria targeted women who planned for a vaginal delivery or those who underwent an unplanned, emergency caesarean. All interventional and observational studies were deemed eligible.

Our primary endpoint was S-PPH, defined as a composite of blood loss of at least 1,000 mL, or a second-line treatment (uterine suture, pelvic vessel ligation, arterial embolization, hysterectomy), PPH-related blood transfusion, peripartum decrease in haemoglobin level, PPH-related maternal death. This outcome definition was selected because it was consistent with the WHO definition of S-PPH. 1

QUALITY ASSESSMENT AND DATA EXTRACTION

The quality of studies was assessed using both the STROBE and CONSORT checklists, as appropriate for observational studies and RCTs. 8, 9

Data extraction was performed in duplicate using a standardized form by two independent researchers (TS and PG). Inter-observer discrepancies were again resolved by arbitration of the same third reviewer (MS).

DATA ANALYSIS
BIAS ASSESSMENT

Bias analysis was adapted from both interventional and observational study designs. It was conducted with reference to the classic biases identified in the Cochrane Handbook or in Jean Bouver’s epidemiology textbook (selection, performance, detection, attrition, classification, evaluation, and confusion biases). 10, 11 We rated biases in each study as “absent” (-), “possible” (+), “probable” (++), “highly probable” (+++), or “not applicable” (N/A).

EVALUATION OF RISK FACTORS FOR S-PPH

Risk factors for S-PPH were gauged using odds ratios (OR) and their 95% confidence interval (CI). Strength was defined for OR>2.0. They were classified as “key established” or of “uncertain significance” determinants using the Bradford Hill criteria’s framework for causal inference, under a pragmatic approach devised to comply with modern-day issues. 12, 13 Concretely, each of the factors identified through data extraction was gauged using the Bradford Hill criteria (strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy) causality framework to determine the causative nature of the pathway between exposure to this factor and S-PPH. Causation and mediation were investigated using directed acyclic graphs, as done routinely in epidemiological practice.

Factors matching at least three of the abovementioned criteria, or two criteria while being linked to a known cause of bleeding (well-known aetiology of PPH, inherited or acquired haemorrhagic disease) were considered as “key established” determinants (involving the probability of a “causal pathway”, based on this abovementioned composite definition).

Factors matching one or two criteria without being linked to a known cause of bleeding were classified as of “associated uncertain status” and recommended for being explored in further study.

Factors accompanying development or progression of S-PPH, without matching any of the abovementioned criteria, nor being linked to a known cause of bleeding, were considered as indicators (or markers) of risk. By this, we mean factors indicating a risk of PPH without necessarily intervening in the causal chain between exposure and event.

RESULTS

The selection process of the articles fulfilling the eligibility criteria for our systematic review is presented in Figure 1.

SELECTED STUDIES

We identified 1,193 potentially relevant, non-duplicate studies. After reviewing the full text of these publications, we found a total of eleven articles that met our inclusion criteria.
CHARACTERISTICS OF SELECTED STUDIES

The descriptive characteristics of the retrieved studies including the period, location, study design, duration of enrolment, and the monocentric or multi-centric organisation of the fourteen selected studies, as well as the statistical method used for classifying risk factors in each of them, are summarized in Table 1.

Figure 1
PRISMA flowchart. Summarizes the selection of the articles included in this literature review.
Table 1. Descriptive characteristics of selected studies

| Authors | Study location, period | Study design | Inclusion (months) | Population (inclusion criteria) | Outcome measure | Analysis |
|---------|------------------------|--------------|--------------------|----------------------------------|-----------------|----------|
| Al Zirqi et al, Sep. 2008 (15) | Norway, 1999 – 2004 | Multicentric retrospective cohort study | 48 | Cohort n= 307,415 (SPPH n=3,501) | 1: SPPH: >1,500 mL or blood transfusion | Multivariate logistic regression |
| Briley et al, Feb. 2014 (17) | United Kingdom, 08/2008 - 07/2009 | Bicentric prospective Cohort study | 12 | Cohort n=10,213-> 9,937 (PPH n=3,349; SPPH n=936) | 1: PPH: >500 mL | Multivariate logistic regression |
| Deneux-Tharaux et al. Jun. 2010 (21) | France 09/2004 - 11/2005, 09/2005 - 11/2006 | Multicentric cluster randomized controlled trial | 27 | Trial population n=146,781 (SPPH n=2,414) | 1: SPPH: blood transfusion, second-line treatment, decrease in Hb ≥4 g/dL, ICU transfer, death | Multivariate logistic regression (random intercept mixed model) |
| Driessen et al, Jan. 2011 (22) | France, 12/2004 - 11/2006 | Multicentric prospective cohort study | 24 | PPH from uterine atony n=4,550 Including SPPH n=952 | SPPH: decrease in Hb ≥4g/dL | Multivariate random-intercept hierarchical logistic regression |
| Dupont et al, May 2014 (24) | France, 12/2005 - 11/2006 | Multicentric Prospective cohort study | 27 | Cohort n=146,781 (PPH n=9,364; SPPH n=2,494) | 1: PPH: >500mL, decrease in Hb ≥2g/dL. | Multivariate logistic regression |
| Gayat et al, Jul. 2011 (23) | France, 01/2004 -12/2005 | Monocentric retrospective cohort study | 24 | PPH n=257 including SPPH n=110 | SPPH: uterine embolization, balloon tamponade, pelvic vessel ligation and/or hysterectomy | Multivariate logistic regression |
| Marocchini et al, May 2006-2014 | France, | Multicentric rétrospective Cohort Lariboisière | Cohort n=156047 including SPPH n=1136 | Blood transfusion | Multivariate logistic regression |
### Table

| Authors                  | Study location, period | Study design                          | Inclusion (months) | Population (inclusion criteria)                      | Outcome measure                                                                 | Analysis                        |
|--------------------------|------------------------|---------------------------------------|--------------------|------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------|
| Helman et al, Apr. 2015 (18) | Israel, 07/ 2005 - 02/ 2014 | Cohort                               | 24                 | n=113,342 (SPPH n=122)                               | SPPH: blood transfusion (5 RBCs)                                                 | Multivariate logistic regression |
|                         |                        | Monocentric case-control (1/4) study |                    |                                                      |                                                                                  |                                 |
| Karlsson et al, Jul. 2015 (19) | Sweden, 06/ 2013 - 03/ 2014 | Multicentric prospective cohort study | 10                 | n=1,951 (SPPH n=250)                                 | SPPH: > 1,000mL (measure not specified)                                          | Multivariate logistic regression |
| Kramer et al, Jul. 2013 (27) | Canada, Montreal, USA, Atlanta, 1999 - 2008 | Multicentric retrospective cohort study | 108                | PPH n=240,472, SPPH n=25,906                        | SPPH: PPH + blood transfusion, PPH + hysterectomy and/or blood transfusion and/or uterine surgery w/o hysterectomy and/or blood transfusion | Multivariate logistic regression |
|                         |                        |                                       |                    |                                                      |                                                                                  |                                 |
| Nyflot et al, Jan.2017 (16) | Norway, 2008-2011       | Bicentric retrospective, Case control | 48                 | Population n=43105, SPPH n=1064                     | SPPH: > 1,500 mL or blood transfusion                                            | Multivariate logistic regression |
| Paglia et al, 2012 (20)    | USA, Durham, 2000 - 2004 | Monocentric case-control study        | 60                 | n=218 deliveries in the case-control group (12,476 in the source population), PPH n=671 including SPPH n=109 | SPPH: PPH + blood transfusion                                                   | Multivariate logistic regression |
|                         |                        |                                       |                    |                                                      |                                                                                  |                                 |
| Sosa et al, Jun. 2009 (28) | Uruguay, Argentina, 12/10/2003 -12/0/2005 | Multicentric prospective cohort       | 24                 | Cohort n=11,323 (PPH n=1,221; SPPH n=209)          | PPH: > 500 mL                                                                   | Multivariate cluster logistic regression |
|                         |                        |                                       |                    |                                                      |                                                                                  |                                 |
| Tort et al, Nov.2016 (26)  | Benin Mali, 2013-2014    | Multicentric prospective cohort       | 17                 | Cohort:22666, PPH:223, SPPH:88                     | SPPH: PPH+ surgery or blood transfusion or death                                 | Multivariate logistic regression |

SPPH – severe postpartum haemorrhage, PPH – postpartum haemorrhage
Factors associated with severe postpartum haemorrhage: systematic review using Bradford Hill’s causality framework

Table 2. Evaluation of study quality with bias analysis

| Study/bias          | Selection | Performance | Detection | Attrition | Classification | Evaluation | Confounding |
|---------------------|-----------|-------------|-----------|-----------|----------------|------------|-------------|
| Al Zirqi et al. (15)| +         | N/A         | N/A       | -         | +              | ++         | +           |
| Briley et al. (17)  | ++        | N/A         | N/A       | -         | ++             | +++        | +           |
| Deneux-Tharaux et al. (21) | -       | ++         | +         | -         | N/A            | +          | +           |
| Driessen et al. (22) | +         | N/A         | N/A       | -         | +              | ++         | +           |
| Dupont et al. (24)  | ++        | N/A         | N/A       | +         | +              | ++         | +           |
| Gayat et al. (23)   | +++       | N/A         | N/A       | +         | ++             | ++         | +++         |
| Marocchini et al. (25)| +      | N/A         | N/A       | +         | ++             | +++        | +++         |
| Helman et al. (18)  | +++       | N/A         | N/A       | -         | ++             | +++        | +++         |
| Karlsson et al. (19) | +++       | N/A         | N/A       | +         | ++             | +++        | +++         |
| Kramer et al. (27)  | ++        | N/A         | N/A       | -         | ++             | ++         | +           |
| Nyflot et al. (16)  | ++        | N/A         | N/A       | -         | +              | ++         | +           |
| Paglia et al. (23)  | ++        | N/A         | N/A       | -         | ++             | +++        | +++         |
| Sosa et al. (28)    | +         | N/A         | N/A       | -         | +              | ++         | +           |
| Tort et al. (26)    | +         | N/A         | N/A       | -         | ++             | +++        | ++          |

no bias (+), possible bias (++), probable bias (+++), highly probable bias (++++)
N/A – not applicable

The selected studies belonged to several study designs, as follows: cohort study (n=10), case-control study (n=3), and cluster randomized clinical trial (n=1). Inclusion periods ranged from ten months to nine years.

The total study population was composed of 9,271,519 parturient women (including 146,781 participants of the Pi-thagore-6 cluster randomized clinical trial). The number of cases of S-PPH was of 35,825 representing 3.9% of all childbirths.

In studies for which the proportion of S-PPH among all cases of PPH could be measured, the average proportion of S-PPH was of 25%. This figure differs slightly from the usually accepted ratio of one S-PPH for five PPH (20%).

The primary endpoint of each study fulfilled the outcome measure previously established in our review protocol. However, the definition of S-PPH varied across studies according to whether the selected outcome was single or composite.

RISK OF BIAS IN SELECTED STUDIES

Biases were independently evaluated for each study. Their analysis is summarized in Table 2.

For example, the study by Briley et al. was deemed to be potentially prone to a moderate selection bias given the small representativeness of this bicentric study and the use of secondary subsampling withdrawing the majority of PPH cases. Together with a 14% error rate in estimated blood loss, we considered it was also affected by a highly probable classification bias, while other biases were considered negligible.

FACTORS ASSOCIATED WITH S-PPH

The full assessment of risk factors using Bradford Hill’s criteria is displayed in Appendix S3 of the Online Supplementary Document.

INDIVIDUAL RISK FACTORS

AGE

Six studies showed that maternal age of 35 years or above were associated with PPH in a significant, consistent, and coherent manner. In addition, Kramer et al. also showed a significant association between PPH and maternal age less than 19 years and the role of first pregnancy at older age on risk of S-HPP was highlighted. Indeed, the risk of S-PPH appears to be U-shaped, being higher before 19 and after 35 years.

BODY MASS INDEX

In the study by Briley et al., the body Mass Index (BMI) was associated with a linear increase of the S-PPH risk (OR 1.04, 95% CI=1.01-1.06, per one-unit increase). In the study by Nyflot et al., obese women (BMI>30) were slightly more at
risk of S-PPH (OR 1.29, 95% CI=1.02-1.63) 19, while in turn, Paglia et al. found a higher risk of S-PPH when the parturient had a BMI less than 50 kg/m². 20 These seemingly contradictory results do not allow us to conclude about the risk's direction between BMI and S-PPH.

ETHNICITY

The risk of S-PPH was lower among patients from the Middle East (OR 0.60, 95% CI=0.45-0.81) but was higher among patients from Southeast Asia (OR 1.77, 95% CI=1.48-2.12) than it was among European patients. 14 Another study found a strong risk (OR>2.0) of PPH in Hispanic populations (OR 3.14, 95% CI=1.25-9.32), as compared with Caucasians. 20

SOCIAL CONTEXT

The study by Briley et al. was the only to focus on the impact of patients' neighbourhood, income level, and educational skills (these variables feeding an "index of multiple deprivation") on PPH. 16 Importantly, it showed that a disadvantaged neighbourhood was associated with an increased risk of severe PPH (OR 1.82, 95% CI=1.10-5.00).

OBSTETRICAL HISTORY

PREVIOUS CAESAREAN

The studies by Al Zirqi et al. (OR 1.46, 95% CI=1.02-2.20), Helman et al. (OR 2.75, 95% CI=1.42-5.53), and Kramer et al. (OR 1.5, 95% CI=1.2-1.3) found an association between a history of caesarean and S-PPH. 14, 21, 18 These results are consistent, plausible, and coherent. They also met the criterion of temporality, according to which exposure precedes the effect. In agreement, a history of previous caesarean section was deemed a key established determinant of S-PPH.

PREVIOUS PPH

The strength of the association between a history of previous PPH and subsequent postpartum bleeding was consistent 19, 16, 22, 17 (underline). Ditto, the criterion of temporality was met. In agreement, a history of previous PPH was deemed a key established determinant of S-PPH.

PARITY

Al Zirqi et al. (OR 1.10, 95% CI=1.02-1.19), Driessen et al. (OR 1.88, 95% CI=1.51-2.33) and Dupont et al. (OR 1.71, 95% CI=1.43-2.05), reported an association between parity and S-PPH. 14, 22, 17 It was less clear for multiparity. Given these discrepancies through parity, we concluded that regarding S-PPH, parity was a factor of uncertain significance.

COURSE OF PREGNANCY

MULTIPLE PREGNANCY

Eight studies showed a strong association between multiple pregnancy and severe bleeding. 14, 21, 22, 23 These results met the criteria of strength, consistency, plausibility, and coherence. Multiple pregnancy was considered as a key established determinant of S-PPH.

EMBRYONIC ANNEXES (PLACENTA, AMNIOTIC MEMBRANES, UMBILICAL CORD)

Abnormal placentation led to S-PPH (OR 7.05, 95% CI=2.26-22.05). 24 Kramer et al. confirmed this association with placenta praevia and placenta abruption (OR 7.00, 95% CI=6.60-7.30) 18, though Marocchini et al. found a very strong association between placenta praevia and S-PPH (OR 22.00). 25 In addition, Briley et al. specified that the risk of S-PPH was the higher with anterior placental presentation (OR 5.55, 95% CI=1.29-23.90). 16 Kramer et al. showed a significant increase in the risk of PPH in the presence of polyhydramnios and chorioamnionitis. 18

Given the strength, consistency, and plausibility of these results, we considered abnormal placentation as a key established determinant for S-PPH.

PREGNANCY-INDUCED HYPERTENSIVE DISORDERS

Although no association was found between preeclampsia and PPH, the strength and the dose-response relationship between pregnancy-induced hypertensive disorders and S-PPH found consistently in the literature support a causal association. 16, 20 Moreover, eclampsia complicated by a HELLP Syndrome (Haemolysis, Elevated Liver enzyme levels, Low Platelet count) was strongly and consistently associated with life-threatening haemorrhages. 14, 23

Given the coherence of these results, we classified preeclampsia as a key established determinant for S-PPH and low platelet counts as a key established indicator.

UTERINE FIBROIDS

Uterine fibroids increased the risk of PPH in the study by Nyfløt et al. (OR 2.51, 95% CI=1.36-4.64) 19 and in the study by Kramer et al. (OR 2.00, 95% CI=1.80-2.20). 18 Given uterine fibroids are known to cause bleeding in other circumstances (eg, menstruations), this association was found coherent, strong, and in accordance, uterine fibroids were considered as a key established obstetrical determinant of S-PPH.

ASSISTED REPRODUCTION

In vitro fertilization (IVF) or intra-cytoplasmic sperm injection (ICSI) increased the risk of S-PPH in the study by Nyfløt et al. (OR 2.72, 95% CI=1.95-3.85). 19

MEDICATIONS

Two studies assessed the impact of medications taken during pregnancy on S-PPH. 16, 20 The use of corticosteroids for foetal lung maturation was associated with an increased risk of S-PPH (OR 2.0, 95% CI=1.2-3.4). 16 Magnesium injection, as used for alleviating preeclampsia, was also associated with S-PPH (OR 5.4, 95% CI=1.8-20.1). 20 Both were deemed as indicators (markers of risk) of S-PPH.

GESTATIONAL AGE

An increased risk of S-PPH was shown for deliveries occurring before 37 weeks gestation (OR 5.0) (25), or after 41 weeks gestation (OR 1.30, 95% CI=1.08-1.56). 17 Women whose infant was very small-for-gestational age (< 3rd percentile) were more likely to be transfused for S-PPH. 23 These two studies did not allow us to draw a firm conclusion and this factor was classified as of uncertain significance.

ACTIVE PHASE OF LABOUR

OXYTOCIC DRUGS

Eight studies assessed the role of oxytocic drugs, used for labour induction, in S-PPH. 14, 21, 17, 18, 15 Two was inconclusive 16, 20, four of these showed a weak association
(OR between 1.1 and 1.7)\textsuperscript{14, 19, 17, 18}, whereas two found a strong association (OR>2.0).\textsuperscript{21, 15}\textsuperscript{5} The consistency, the coherence with current knowledge and temporality led us to consider labour induction as a key established determinant of S-PPH.

**LABOUR DURATION**

Prolonged active phase of labour, known to alter muscle contractility, was associated with an increased risk of S-PPH.\textsuperscript{14, 19, 22, 17} In addition, Dupont et al. emphasised that bleeding risk was higher when the active phase of labour exceeded six hours (OR 1.70, 95% CI=1.143-2.01).\textsuperscript{17} Given the consistency and plausibility of these results, we concluded that prolonged labour is a key established determinant for S-PPH, without further confirming the six-hour time limit.

**UTERINE RUPTURE**

Uterine rupture, a complication that occurs mostly during the active phase of labour, has been recognised as cause of obstetric haemorrhage. The study by Kramer et al. confirmed a very strong association between uterine rupture and S-PPH (OR 23.0, 95% CI=14.3-37.1).\textsuperscript{18} Given the consistency and coherence of these results, we found a strong association between placenta re-
tention and S-PPH (OR 23.0, 95% CI=14.3-37.1).\textsuperscript{25} These findings are highly coherent with current knowledge and recommenda-
tions.

**FOETAL PRESENTATION**

Kramer et al. showed that breech presentation increased the risk of S-PPH (OR 1.2, 95% CI=1.1-1.2).\textsuperscript{18} However, this single study did not allow us to draw a firm conclusion conducting this factor to be considered as of uncertain signifi-
cance.

**DELIVERY COMPLICATIONS**

Sosa et al. found a strong association between placenta re-
tention and S-PPH (OR 16.0, 95% CI=7.1-36.0).\textsuperscript{13} Karlsson et al. highlighted a strong association between uterine exploration (usually an indicator of placenta retention) and risk of S-PPH (OR 23.0, 95% CI=14.3-37.1).\textsuperscript{25} These findings are highly coherent with current knowledge and recommen-
dations.

**LESSONS IN THE BIRTH CANAL**

Cervical laceration was shown strongly associated with bleeding risk (OR 94.0, 95% CI=87.3-101.2).\textsuperscript{18} Together with the plausibility and coherence of these results, this strong association led us to conclude that if such a birth canal injury (cervical or vaginal laceration, episioto-
my) was not sutured in the shortest time possible, blood loss would be substantial. In agreement, cervical injury was considered as a key established determinant of S-PPH.

**BIRTHWEIGHT**

Five studies an association between foetal macrosomia and the risk of S-PPH.\textsuperscript{14, 19, 17, 18, 15} The consistency and the coherence of these results with current knowledge led us to propose foetal macrosomia as a key established determinant of S-PPH, even though it may not be causal, this increasing the risk of other contributors on the causal pathway to S-PPH like, for instance, the les-
ions of birth canal.

**BIOLICAL PARAMETERS**

Low pre-pregnancy or low prepartum haemoglobin levels (<9 g/dL), prothrombin time (PT) below 50%, fibrinogen lev-
el below 2 g/L, and detectable level of Troponin-I before del-
ivery, were considered as indicators of S-PPH.\textsuperscript{14, 19, 24}

**EPIDURAL ANALGESIA**

Several studies examined the relationships between epidur-
al analgesia during labour and S-PPH.\textsuperscript{16, 22, 17} Only two of these showed a weakly protective role (0.5<OR<1.0) of anal-
gesia against S-PPH. Further studies are needed to draw a firm conclusion.

**MANAGEMENT OF SEVERE PPH**

Only four studies reported the impact of the medical man-
agement of labour on the incidence and prevalence of S-
PPH.\textsuperscript{26, 22, 17, 27} Importantly, Deneux-Tharaux et al. found no risk reduc-
ction in women exposed to a multifaceted intervention for reducing the incidence of S-PPH.\textsuperscript{26} In the Pithagore-6 cluster RCT similar incidence rates of S-PPH were observed in both the intervention arm (discussion of recommendations, reminders, audit) and the control group (passive diffusion of information). With respect to oxytocin injected during labour, one study found a protective effect when injected within 10 minutes.\textsuperscript{25} By contrast, Dupont et al. found an overall increased risk of S-PPH (OR 1.26, 95% CI=1.06-1.50)\textsuperscript{17}, while the study by Driessen et al., within the same Pithagore6-trial framework, established that this risk was act-
ual when given beyond 20 minutes after birth (OR 1.49, 95%

**SUMMARY OF FINDINGS**

We distinguished the factors associated with S-PPH into key established determinants, associated factors of uncer-
tain significance, and indicators to guide the obstetrical de-
cision. This classification is summarized in Table 3.
### Table 3. Summary of determinants of severe postpartum haemorrhage

| S- PPH determinants | Socio-demographic | Obstetrical | Delivery | Indicators (biological, medical statements) |
|---------------------|-------------------|-------------|----------|--------------------------------------------|
| Key established     |                   | Previous caesarean, or PPH, | Instrumental vaginal delivery, | Hb<9g/dL, |
|                     |                   | Multiple pregnancy, | Caesarean, | Low platelets, |
|                     |                   | Abnormal placentation | Placental retention, | PT<50%, |
|                     |                   | Preeclampsia, eclampsia, | Uterine exploration, | Fibrinogen<2g/dL, |
|                     |                   | Cervical maturation, | Cervical injury, | Troponin I (detectable) |
|                     |                   | Labour induction, |                         |                |
|                     |                   | Prolonged duration of labour, |                         |                |
|                     |                   | Uterine fibroids, |                         |                |
|                     |                   | Uterine rupture. |                         |                |
| Uncertain significance | Age | Parity | Breech presentation | Corticosteroid |
|                      | BMI   |        | Epidural analgesia* | Magnesium intake |
|                      | Etnicity | Gestational age |                         |                |
|                      | Socio-educational level | Oxytocin infusion during labour |                         |                |
|                      | Maternal education |                         |                         |                |

PPH - postpartum haemorrhage, Hb - Haemoglobin level, TP - Prothrombin time, BMI - Body Mass Index, IVF - In vitro Fertilization

*Protective factor.
DISCUSSION

Based on a critical and pragmatic analysis of the literature, we propose that the key established determinants of S-PPH be identified, as follows: previous caesarean, previous PPH, multiple pregnancy, abnormal placentaion, pregnancy-induced hypertensive disorders, labour induction, prolonged labour, uterine rupture, uterine fibroids, instrumental vaginal delivery and caesarean, uterine atony, placental retention, macrosomia and birth canal injuries. In addition, we require further studies to confirm the relevance of reproductive assistance technics (IVF/ICSI), epidural analgesia, gestational age, as well as social factors.

Together with the heterogeneity in the outcome measure definition, the very different study designs, population sizes, and definitions of exposure factors, prevented us to use meta-analysis for providing quantitative estimates of the associations between the candidate determinants and S-PPH.

Despite these limitations, we believe that the pragmatic approach that we used ensures internal validity of our results while minimising publication bias.

We confirm the primarily obstetrical nature of the key determinants of S-PPH. This observation fits current knowledge on the pathogenesis of postpartum bleeding. Among these, we distinguish causes and risk factors according to whether there are no or not mediators on the causal pathway linking exposure to severe bleeding. In agreement, uterine fibroids, abnormal placentaion, preeclampsia, uterine rupture, uterine atony, placental retention, and birth canal injuries, are likely causes of PPH by different pathomechanisms (*fibrinolysis and consumption of clotting factors* and should prompt active management to prevent evolution into S-PPH. By contrast, history of previous caesarean, history of previous PPH, multiple pregnancy, labour induction, prolonged labour, instrumental vaginal delivery and caesarean, require intermediate factors (abnormal placentaion or uterine atony) are favouring conditions to severe bleeding in the third stage of labour or after delivery, which motivates additional explorations and interventions (e.g., timely reinjection of oxytocin, sublingual misoprostol, sulprostone, or early tranexamic acid) to contain blood losses.

Along with uncertain significance of their predictive value, the non-modifiable character of most socio-demographic factors does not support them for guiding obstetrical decision-making.

However, the U-shaped curves of S-PPH risk observed both for maternal age and parity, should prompt caregiver’s awareness to young nulliparae and elderly grand multiparae at the top of the risk of S-PPH, while women with one single of these factors could be considered at an intermediate risk. Interestingly, these U-shaped curves are coherent with those observed in several other perinatal outcomes, such as preterm birth and small-for-gestational age for maternal age, but also with all-cause mortality later in life for parity.

It is recognised that severely obese women with a prepregnancy BMI> 35 kg/m² face multiple perinatal risks. Briley et al. have confirmed the existence of a positive association between maternal weight and S-PPH in a large prospective cohort. The evidence of a biological gradient between an increasing BMI and a higher risk of S-PPH likely supports causality. Actually, the finding suggest that maternal obesity has a modest effect on haemorrhage risk: the direction of the association may differ by delivery mode. The role of ethnicity in S-PPH is less clear and may differ according to both socio-environmental context and genetic factors. Briley et al. have suggested that Black African women were more likely to have PPH. In other studies, Southeast Asian and Hispanic women were the more at-risk of S-PPH, while Middle Eastern women seemed protected. Importantly, these ethnic groups at-risk have been confirmed recently in a large hospital-based study conducted in the US, in comparison to Non-Hispanic White, the lower-risk group, independently of confounding factors, including insurance status. Interestingly, among seven candidate genes, promoter polymorphism of the tissue factor gene (F3–605A>G) showed a significant association with PPH after adjustment for known risk factors, fuelling the idea of a genetic background that supports role of ethnicity in S-PPH. However, this hypothesis is challenged by another observation in low-income American women of increased risks of PPH with antidepressants uptake, independently of numerous confounders including race.

During the last decade, the growing interest in reviews of clinical practices and the commitment to identifying suboptimal care has led to investigate the factors related to the management of PPH, both collectively and individually.

At maternity level, despite the inconclusive Pithagore-6 cluster RCT, community-based multifaceted interventions, aimed at improving the translation into clinical practices of the guidelines for PPH management, have gained attention in recent years and even proved effectiveness in low-middle income countries.

At individual level, oxytocin infusion is mandatory for the prevention of third-stage labour and postpartum bleeding risks. In the presence of PPH, re-administration of oxytocin should be prompt, as it was shown ineffective when performed more than 20 min after onset of PPH to avoid progression towards S-PPH. In addition, caution should be the rule as treatment with oxytocin was associated with a harmful dose-response in a population-based nested case-control study (i.e., the higher the dose, the more severe the bleeding), which emphasises the need for more evidence-based indications and the minimal useful regimens.

Epidural analgesia was found protective for the risk of S-PPH in two studies. This practice ensures comfort to parturient women and allows effective and rapid intervention in life-threatening obstetric emergencies. However, its benefits must be weighed against a potential decrease in uterine contractility, and hence against increased duration of labour, with expected difficulties in foetus expulsion.

We found four biological parameters, Troponin-I, haemoglobin, PT, and fibrinogen that seemed mere indicators of S-PPH as they are not clearly located on the causal pathway between exposure and disease. Among these, given that fibrinolysis may be important in S-PPH pathogenesis, only fibrinogen has paid attention so far, and multicenter trials testing the effectiveness of fibrinogen concentrates are currently underway.

Our systematic review has strengths and limitations. The attachment to the PRISMA statement throughout the different steps of this systematic review adds scientific rigour in the reporting of the results.

In the absence of consensual definition, we defined S-PPH as primary endpoint using the WHO definition. As a consequence, we excluded from our systematic review studies that used the former definition of S-PPH, such as Canadian and Italian studies.

Our systematic review covers a wide range of geographic areas including North and South America, Southern and Northern Europe, West Africa, and Israel. It gathers a very large population, which provides...
external validity and ensures extrapolations.

In a global context in which S-PPH remains the leading cause of maternal mortality, we rigorously gauged factors associated with S-PPH and distinguished key established determinants, as well as associated factors (especially contextual factors) and indicators that warrant further studies. We highlight socio-environmental factors and propose new studies to specify the impact of emerging factors on PPH, to take into account the context in which the disease occurs, and organise emergency obstetric care distribution and accessibility. In the field of obstetrical care, in which practices move faster than the pace of new publications, we endorse the concept of "living" systematic reviews and encourage regular updates of the current knowledge on S-PPH determinants combining rigour with timeliness. 43

ACKNOWLEDGEMENTS

This work results of an internship of Master degree in clinical epidemiology. Tatiana Stachetti thanks the team of the CIC1410 for its warm welcoming during her internship, as well as Prof Laetitia Huiart, Head of the the CIC, for her supervision. The authors are indebted to Monsieur Jacques Gonthier, documentalist, to ease access to bibliography. Tatiana Stachetti also thanks Dr Marie Devred, gynaecologist-obstetrician, for her clinical expertise, guidance and proofreading. Patrick Gérardin thanks Dr Philippe Guillermin, gynaecologist-obstetrician, for furthering clinical research on PPH within the CIC. They also thank the teachers of the Master at the Institute of Public Health, Epidemiology and Development (ISPED), Bordeaux, especially Prof Rachid Salmi, Prof Rodolphe Thiénaut and Dr Karen Leffondre, for their precious advices as well as their colleagues for dedicated care to women’s health.

Competing interests: The author completed the Unified Competing Interest form at http://www.icmje.org/coi_dislosure.pdf (available upon request from the corresponding author), and declare no conflicts of interest.

Correspondence to: Madame Tatiana Stachetti
INSERM CIC1410
Clinical Epidemiology, Pôle Anesthésie
Centre Hospitalier Universitaire (CHU) Réunion
BP 350, 97448 Saint Pierre Cedex
Réunion
tatiana.stachetti@chu-reunion.fr

Dr Patrick Gérardin
INSERM CIC1410
Clinical Epidemiology
CHU de la Réunion
Groupe Hospitalier Sud Réunion
BP 350, 97448 Saint Pierre Cedex
Réunion
patrick.gerardin@chu-reunion.fr

Funding: None.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license's legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.
REFERENCES

1. Recommendations WHO. for the Prevention and Treatment of Postpartum Haemorrhage - PubMed - NCBI. https://www.ncbi.nlm.nih.gov/pubmed/23586122.

2. Obstetricians RC, Gynaecologists. Postpartum hemorrhage: Prevention and management. 2011. http://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg52/.

3. Sentilhes L, Merlot B, Madar H, Sztark F, Brun S, Deneux-Tharaux C. Postpartum haemorrhage: Prevention and treatment. Expert Review of Hematology. 2016;9(11):1043-1061. doi:10.1080/17474086.2016.1245135

4. Bonnet M-P. Postpartum Hemorrhage: Epidemiological profile and assessment of anesthesia and intensive care practices in France (Internet. In: Theses). Université Pierre et Marie Curie. Paris VI; 2014. https://tel.archives-ouvertes.fr/tel-00978795.

5. Tessier V, Pierre F. Collège National des Gynécologues et Obstétriciens Français, Agence Nationale d’Accréditation et d’Évaluation en Santé. (Risk factors of postpartum hemorrhage during labor and clinical and pharmacological prevention. :29-224.

6. Goffinet F, Mercier F, Teyssier V, et al. Hémorragies du post-partum : Recommandations du CNGOF pour la pratique clinique (décembre 2004). Gynécologie Obstétrique & Fertilité. 2005;33(4):268-274. doi:10.1016/j.gyobfe.2005.03.016

7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

8. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453-1457. doi:10.1016/s0140-6736(07)61028-x

9. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology. 2010;63(8):e1-e57. doi:10.1016/j.jclinepi.2010.03.004

10. Cochrane Handbook for Systematic Reviews of Interventions. Accessed. September 2018. https://training.cochrane.org.

11. Bouyer J, Hénon D, Cordier S, Derriennic F, Stücker I, Stengel B, et al. Librairie Lavoisier. http://www.lavoisier.fr/livre/medecine/epidemiologie/bouyer/descriptif-9782743011673.

12. Hill AB. The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine. 1965;58(5):295-300. doi:10.1177/00359157650580503

13. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: How data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12(1). doi:10.1186/s12982-015-0057-4

14. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG: An International Journal of Obstetrics & Gynaecology. 2000;117(10):1265-1272. doi:10.1111/j.1471-0528.2000.tb02013.x

15. Sosa CG, Althabe F, Belizán JM, Buekens P. Risk factors for postpartum hemorrhage in vaginal deliveries in a Latin-American population. Obstetrics & Gynecology. 2009;113(6):1315-1319. doi:10.1097/aog.0b013e3181a66b05

16. Briley A, Seed P, Tydeman G, et al. Reporting errors, incidence and risk factors for postpartum haemorrhage and progression to severe PPH: A prospective observational study. BJOG: Int J Obstet Gy. 2014;121(7):876-888. doi:10.1111/1471-0528.12588

17. Dupont C, Rudigoz R-C, Cortet M, et al. Incidence, étiologies et facteurs de risque de l’hémorragie du post-partum : étude en population dans 106 maternités françaises. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2014;43(5):244-253. doi:10.1016/j.jgyn.2013.05.003

18. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. American Journal of Obstetrics and Gynecology. 2013;209(5):449.e1-449.e7. doi:10.1016/j.ajog.2013.07.007

19. Nyfløt LT, Sandven I, Stray-Pedersen B, et al. Risk factors for severe postpartum hemorrhage: A case-control study. BMC Pregnancy Childbirth. 2017;17(1). doi:10.1186/s12884-016-1217-0
20. Paglia MJ, Grotegut CA, Johnson LNC, Thames B, James AH. Body mass index and severe postpartum hemorrhage. *Gynecol Obstet Invest*. 2012;73(1):70-74. doi:10.1159/000329355

21. Helman S, Drukker L, Fruchtman H, et al. Revisit of risk factors for major obstetric hemorrhage: Insights from a large medical center. *Arch Gynecol Obstet*. 2015;292(4):819-828. doi:10.1007/s00404-015-3725-y

22. Driessen M, Bouvier-Colle M-H, Dupont C, Khoshnood B, Rudigoz R-C, Deneux-Tharaux C. Postpartum Hemorrhage Resulting From Uterine Atony After Vaginal Delivery. *Obstetrics & Gynecology*. 2011;117(1):21-31. doi:10.1097/aog.0b013e318202ec845

23. Marocchini M, Lauféron J, Quantin C, Sagot P. Postpartum hemorrhage with transfusion: Trends, near misses, risk factors and management at the scale of a perinatal network. *Journal of Gynecology Obstetrics and Human Reproduction*. 2017;46(5):455-460. doi:10.1016/j.jogoh.2017.03.011

24. Gayat E, Resche-Rigon M, Morel O, et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. *Intensive Care Med*. 2011;37(11):1816-1825. doi:10.1007/s00134-011-2315-0

25. Karlsson O, Jeppsson A, Thornemo M, Larenz H, Rådström M, Hellgren M. Fibrinogen plasma concentration before delivery is not associated with postpartum haemorrhage: A prospective observational study. *British Journal of Anaesthesia*. 2015;115(1):99-104. doi:10.1093/bja/aev039

26. Deneux-Tharaux C, Dupont C, Colin C, Rabilloud M, Touzet S, Lansac J. Multifaceted intervention to decrease the rate of severe postpartum haemorrhage: The pithagore6 clster-randomised controlled trial. *J Matern Fetal Neonatal Med*. 2010;S1(609):23-24.

27. Tort J, Traoré M, Hounkpatin B, Bodin C, Rozenberg P, Dumont A. Initial management of postpartum hemorrhage: A cohort study in Benin and Mali. *International Journal of Gynecology & Obstetrics*. 2016;135(S1):S84-S88. doi:10.1016/j.iigo.2016.08.016

28. Bonnet MP, Benhamou D. Management of postpartum haemorrhage. *F1000Res*. 2016;5:1514. doi:10.12688/f1000research.7836.1

29. Gülmezoglu AM, Villar J, Ngoc NTN, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. *The Lancet*. 2001;358(9283):689-695. doi:10.1016/s0140-6736(01)05835-4

30. Atukunda EC, Siedner MJ, Obua C, Muyenyi GR, Twagirumukiza M, Agaba AG. Sibling misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: A double-blind randomized non-inferiority trial. *Middleton P*, ed. *PLoS Med*. 2014;11(11):e1001752. doi:10.1371/journal.pmed.1001752

31. Poeschmann RP, Doesburg WH, Eskes TKAB. A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. *BJOG: An international journal of O&G*. 1991;98(6):528-530. doi:10.1111/j.1471-0528.1991.tb10364.x

32. Collaborators WOMANT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;389(10075):2105-2216. doi:10.1016/s0140-6736(17)30638-4

33. Dior UP, Hochner H, Friedlander Y, et al. Association between number of children and mortality of mothers: Results of a 57-year follow-up study. *Annals of Epidemiology*. 2013;23(1):15-18. doi:10.1016/j.annepidem.2012.10.005

34. Liu L, Hong Z, Zhang L. Associations of prepregnancy body mass index and gestational weight gain with pregnancy outcomes in nulliparous women delivering single live babies. *Sci Rep*. 2015;5(1). doi:10.1038/srep12863

35. Butwick AJ, Abreo A, Bateman BT, et al. Effect of Maternal Body Mass Index on Postpartum Hemorrhage. *Anesthesiology*. 2018;128(4):774-783. doi:10.1097/ALN.0000000000002082

36. Grobman WA, Bailit JL, Rice MM, et al. Racial and ethnic disparities in maternal morbidity and obstetric care. *Obstetrics & Gynecology*. 2015;125(6):1460-1467. doi:10.1097/aog.0000000000000735

37. Biguzzi E, Franchi F, Acaia B, et al. Genetic background and risk of postpartum haemorrhage: Results from an Italian cohort of 3219 women. *Haemophilia*. 2014;20(6):e577-e383. doi:10.1111/hae.12514

38. Palmsten K, Hernandez-Diaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: Cohort study of low income women in the United States. *BMJ*. 2013;347(aug21 2):f4877-f4877. doi:10.1136/bmj.f4877
39. Liabsuetrakul T, Palanukunwong K, Chinduereh A, Oumudee N. Evaluation of a multifaceted postpartum hemorrhage-management intervention in community hospitals in Southern Thailand. *Int J Gynecol Obstet*. 2017;139(1):39-44. doi:10.1002/ijgo.12253

40. Belghiti J, Kayem G, Dupont C, Rudigoz R-C, Bouvier-Colle M-H, Deneux-Tharaux C. Oxytocin during labour and risk of severe postpartum haemorrhage: A population-based, cohort-nested case-control study. *BMJ Open*. 2011;1(2):e000514-e000514. doi:10.1136/bmjopen-2011-000514

41. Mehrabadi A, Liu S, Bartholomew S, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. *Journal of Obstetrics and Gynaecology Canada*. 2014;36(1):21-33. doi:10.1016/s1701-2163(15)30680-0

42. Biguzzi E, Franchi F, Ambrogi F, et al. Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women. *Thrombosis Research*. 2012;129(4):e1-e7. doi:10.1016/j.thromres.2011.09.010

43. Elliott JH, Turner T, Clavisi O, et al. Living systematic reviews: An emerging opportunity to narrow the evidence-practice gap. *PLoS Med*. 2014;11(2):e1001605. doi:10.1371/journal.pmed.1001605